The Brazilian National Health Surveillance Agency (Anvisa) released on Tuesday (6) the sale and use of new drug against hepatitis C: the Declastavir.
The new drug is more effective than those available in the market today and, combined with two other substances, can allow a cure in 90% of cases, while current treatments have 40% cure perspective.
The forecast is that the medicine is distributed for free by the Unified Health System (SUS) also in 2015.
For the Health Minister Arthur Chioro, free distribution of the drug represents a revolution for public health and transform Brazil into an international reference in the treatment of hepatitis C.
“We are living a revolution that size was the introduction of the cocktail for the treatment of AIDS in Brazil, both by decreased treatment time and by increased cure rate rising from 40% to 90%. Furthermore, side effects are much less severe, which increases the adhesion and the ability of patients to remain with medication “, said Chioro.
Currently in Brazil, 16 000 people perform the treatment for hepatitis C SUS.According to estimates by the Ministry of Health, 30,000 people will be benefited by year with the new treatment.
In addition, the new medication enable cost savings to the individual treatment of patients, falling from the current US $ 25 000 per user for approximately R $ 17 thousand.
Besides allowing healing in 90% of cases, the Declatavir causes few side effects in patients and leads to cure within three months.
Already existing drugs sold in the country cause strong adverse reactions in patients, and require prolonged treatment – up to nine months.
The Declatavir also be the first drug to combat hepatitis C orally distributed in Brazil. Today are all injectable.
Another advantage is that the new treatment against hepatitis C may be used for HIV positive patients and those expected or transplants performed, which is not achievable by existing treatment.
Hepatitis C is a disease caused by HCT virus transmitted by contaminated blood transfusion and the shared use of syringes and personal hygiene objects such as nail pliers and razors, as well as tools used in tattooing and piercing piercings.
The virus is also transmitted sexually. The estimate of the Ministry of Health is that the disease reaches between 1.4% and 1.7% of Brazilians, most over 45 years old.